Details for Patent: 10,030,005

Which drugs does patent 10,030,005 protect, and when does it expire?

Patent 10,030,005 protects GAVRETO and is included in one NDA.

This patent has forty-seven patent family members in thirty-four countries.

Summary for Patent: 10,030,005

Patent landscape, scope, and claims:

Title:	Inhibitors of RET
Abstract:	Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
Inventor(s):	Brubaker; Jason D. (Cambridge, MA), Kim; Joseph L. (Wayland, MA), Wilson; Kevin J. (Boston, MA), Wilson; Douglas (Ayer, MA), DiPietro; Lucian V. (Gloucester, MA)
Assignee:	BLUEPRINT MEDICINES CORPORATION (Cambridge, MA)
Application Number:	15/340,428
Patent Claim Types: see list of patent claims	Use; Composition; Compound;

Drugs Protected by US Patent 10,030,005

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Rigel Pharms	GAVRETO	pralsetinib	CAPSULE;ORAL	213721-001	Sep 4, 2020		RX	Yes	Yes			Y	Y		TREATMENT OF ADULT PATIENTS WITH METASTATIC REARRANGED DURING TRANSFECTION (RET) FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST
Rigel Pharms	GAVRETO	pralsetinib	CAPSULE;ORAL	213721-001	Sep 4, 2020		RX	Yes	Yes			Y	Y		TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)

International Family Members for US Patent 10,030,005

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	106548
Australia	2016348402
Brazil	112018008877